key: cord-1034351-kiw6bhsq
authors: Imran, Mohd; Fatima, Waseem; Alzahrani, A. Khuzaim; Suhail, Nida; Alshammari, Mohammed Kanan; Alghitran, Abdulrahman A.; Alshammari, Fayez Nafea; Ghoneim, Mohammed M.; Alshehri, Sultan; Shakeel, Faiyaz
title: Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents
date: 2022-03-14
journal: Nutrients
DOI: 10.3390/nu14061227
sha: fcc7b0bcb6d4f494d0f22796b2a448984782a0de
doc_id: 1034351
cord_uid: kiw6bhsq

Zinc is an essential nutrient for human health; it is involved in the catalytic, structural, and regulatory functions of the human cellular system. Different compositions of zinc, as well as its pharmaceutically acceptable salts, are available on the market. Recent studies have demonstrated the role of zinc in combating COVID-19. It has been determined that zinc prevents the entry of SARS-CoV-2 into cells by lowering the expression of ACE-2 receptors and inhibiting the RNA-dependent RNA polymerase of SARS-CoV-2. Zinc also prevents the cytokine storm that takes place after the entry of SARS-CoV-2 into the cell, via its anti-inflammatory activity. The authors believe that no study has yet been published that has reviewed the trends, inventions, and patent literature of zinc compositions to treat/prevent COVID-19. Accordingly, this review has been written in order to fill this gap in the literature. The information about the clinical studies and the published patents/patent applications was retrieved from different databases. This review covers patent literature on zinc compositions up to 31 January 2022. Many important patents/patent applications for zinc-based compositions filed by innovative universities and industries were identified. The patent literature revealed zinc compositions in combination with zinc ionophores, antioxidants, antivirals, antibiotics, hydroxychloroquine, heparin, ivermectin, and copper. Most of these studies were supported by clinical trials. The patent literature supports the potential of zinc and its pharmaceutical compositions as possible treatments for COVID-19. The authors believe that countless zinc-based compositions are still unexplored, and there is an immense opportunity to evaluate a considerable number of the zinc-based compositions for use against COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative virus for the contagious coronavirus disease of 2019 . The first SARS-CoV-2 infection

Zinc, a brittle and silver/grey metal in its unoxidized form, is represented by the symbol Zn (atomic number 30); it is the second most abundant metal in the human body, after iron [21] . Zinc is an essential nutrient because it is needed in almost all aspects of cellular/biological processes (i.e., catalytic functions, structural functions, and regulatory functions) of the human body [22] . The catalytic functions of zinc are attributed to its antioxidative nature, and to it being an essential component of~3000 catalytic enzymes (e.g., dismutase, dehydrogenase, anhydrase, carboxypeptidase, aminopeptidase, lyase, metalloproteinase, S-methyltransferase, carboxytransferase, deacylase, hydrolase, nuclease, synthase, etc.) [22, 23] . The structural functions of zinc include maintenance and stabilization of the intracellular components/cell membranes [22, 23] . The regulatory functions of zinc encompass being a component of DNA/RNA polymerase, many kinases, and ribonuclease [22, 23] .

The human body does not have a zinc store, although it can reutilize some of the zinc released after tissue catabolism [24] . Accordingly, zinc should be consumed regularly in the diet-especially through foods of animal origin (e.g., meat, shellfish, etc.)-or as a supplement/medicine in order to prevent its deficiency [22] [23] [24] . The absorption of zinc increases in a diet containing protein, histidine, methionine, and citrate. However, some drugs ( Figure 1 ) and compounds/elements (e.g., phytic acid, cadmium, high doses of iron, and casein) lower the bioavailability of zinc by complexing with it [24] [25] [26] [27] . Accordingly, it is imperative to identify compounds that increase or decrease the absorption of zinc during zinc therapy. The daily zinc requirements for different populations are listed in Table 1 [26, 27] . After ingestion, zinc is released as Zn +2 ions and absorbed up to an extent of 33% in a normal healthy person, wherein a decrease in zinc absorption takes place with an increase in age. The zinc is transported to cells through transport proteins [24, 25] , where it demonstrates its biological effects, including antioxidant, immunostimulant, and antiviral effects ( Figure 1 ). Zinc deficiency can cause many effects, including growth hindrance, delayed sexual development, skin problems, diarrhea, alopecia, decreased appetite, osteoporosis, and increased susceptibility to viral infections. Accordingly, zinc supplements and zinc-based medicines are effective in the treatment of many illnesses (Figure 1 ). At the same time, excessive use of zinc can cause many side effects, and can demonstrate drug-drug and drug-disease interactions ( Figure 1 ) [24] [25] [26] [27] . 

A search for United States Food and Drug Administration (USFDA)-approved zinc products was conducted on the Orange Book of the USFDA [28] on 1 February 2022, using "zinc" as the keyword. A total of 40 products were obtained, out of which 21 were prescription products and 19 have been discontinued. Among the 21 products, 10 belonged to bacitracin zinc salts, and 11 belonged to zinc sulfate (3 products), zinc chloride (2 products), zinc acetate (2 products), and zinc combinations with other salts/drugs (4 products). The results of the search are provided in Table 2 . The USFDA-approved zinc products mentioned in Table 2 are indicated for the parenteral/oral intake of zinc, for maintaining zinc serum levels and avoiding any zinc deficiency syndrome, and for diaper dermatitis (ointment). 

SARS-CoV-2 is an RNA virus containing a spike protein. The virus enters human cells after binding its spike protein with the ACE-2 receptors, which are expressed in many human cells (e.g., lung epithelial cells, vascular endothelial cells, etc.) [6, 8] . Zinc minimizes the activity of sirtuin-1 (SIRT-1), which regulates ACE-2 expression. Accordingly, zinc prevents the entry of SARS-CoV-2 into the cell by lowering the expression of the ACE-2 receptors [29] (Figure 2 ). SARS-CoV-2 also needs RNA-dependent RNA polymerase (RdRp) for its replication. Zinc inhibits the RdRp and prevents the replication of SARS-CoV-2 ( Figure 2 ) [6, 8] . The principal hallmark of COVID-19 infection is an imbalance of the immune system. The intracellular presence of SARS-CoV-2 generates a cytokine storm due to the activation of the NF-κB signaling system, and causes ARDS [30, 31] . Zinc demonstrates its anti-inflammatory effect by suppressing the NF-κB signaling and attenuating the cytokine storm [30, 31] (Figure 2 ). Zinc also stimulates the generation of interferons that help in the synthesis of antiviral proteins (i.e., latent ribonuclease and protein kinase) that degrade the RNA of SARS-CoV-2 [22] . Zinc increases the activity of natural killer cells, cytotoxic cells, and B-cell receptor signaling, and increases the production of antibodies. All of these factors make zinc an excellent remedy against COVID-19 [32] .

A search on the clinical trials database [33] was conducted on 31 January 2022 using the keyword "zinc" in combination with other keywords. This search provided many studies on zinc compositions as treatments for COVID-19 (zinc = 2086 studies; COVID-19 = 7337 studies; zinc + COVID-19 = 68 studies; zinc + COVID = 68 studies; zinc + SARS-CoV-2 = 19 studies; zinc + coronavirus disease 2019 = 4 studies; zinc + coronavirus disease 19 = 2 studies; zinc + severe acute respiratory syndrome coronavirus 2 = 2 studies; zinc + 2019-nCoV = 0 studies; zinc + novel coronavirus = 0 studies; zinc + SARS coronavirus 2 = 0 studies; zinc + Wuhan coronavirus = 0 studies). The interventional clinical studies (Phases 1, 2, 3, and 4) based on zinc compositions are summarized in Table 1 . The complete details of the clinical trials mentioned in Table 3 can be obtained using the NCT numbers in the clinical trials database (https://www.clinicaltrials.gov/ accessed on 31 January 2022). 

The patent exploration was carried out utilizing different patent databases (Sci-Finder, Espacenet, Patentscope, and the USPTO) [34] [35] [36] [37] [38] [39] [40] on 31 January 2022. A combination search for the terms "Zinc + COVID-19" and "Zinc + SARS-CoV-2" was performed in different fields (claims, abstract, and title) of Espacenet, Patentscope, and the USPTO. A similar search was performed in the "Research topic" field of Sci-Finder. The Espacenet database (zinc + COVID-19 = 111 hits; zinc + SARS-CoV-2 = 110 hits), Patentscope database (zinc + COVID-19 = 117 hits; zinc + SARS-CoV-2 = 127 hits), USPTO database (zinc + COVID-19 = 39 hits; zinc + SARS-CoV-2 = 27 hits), and Sci-Finder (zinc + COVID-19 = 155 hits; zinc + SARS-CoV-2 = 65 hits) resulted in a total of more than 150 hits. The duplicate patent references were removed and segregated according to their families.

A patent has two types of claims: independent claims, and dependent claims. The components of the independent claims are the essential parts of the invention. Accordingly, all of the patents/patent applications whose independent claims relating to the use of zinc compositions to treat/prevent COVID-19/SARS-CoV-2 infection were included in this review, and are summarized in Table 4 . The patents/patent applications for zinc-based masks, polymers, fabrics, coatings, and devices were excluded from this review. A synergistic composition comprising one zinc-chelating peptide, one protease inhibitor (9-L-arginine-peptide), and one inhibitor of viral replication enzymes (vitamin B12) [61] (Viral protein synthesis inhibitor; Not present, but in vitro assay present) Our search also revealed some patents/patent applications that implicitly relate to the use of zinc-based compositions to treat/prevent COVID-19/SARS-CoV-2 infection. However, these documents are silent about the anti-COVID-19/antiviral activity of zinc. These documents include US20210244726A1 (a composition of chloroquine/hydroxychloroquine, a macrolide antibiotic, and zinc) [70] , IN202021031040A (an Ayurvedic composition contain-ing zinc) [71] , CN111450100A (a composition of caffeine, chlorogenic acid, and zinc) [72] , WO2021074706A1 (an immunomodulatory composition of many nutrients and zinc) [73] , WO2021183456A1 (a composition of lenzilumab and zinc) [74] , WO2021186396A2 (a composition of artemisinin and zinc) [75] , WO2021195017A1 (an iodine inhalation composition containing zinc) [76] , US20210346453A1 (a composition of Uncaria tomentosa extract containing zinc) [77] , WO2021224356A1 (a composition of plerixafor/burixafor containing zinc) [78] , US20210338765A1 (a composition of ashwagandha, shallaki, ginger, turmeric, and zinc) [79] , US20210330587A1 (an oral sanitizer containing zinc) [80] , WO2021205242A1 (a composition of a synbiotic and zinc) [81] , WO2021205437A1 (a composition of a cholesterol-lowering compound, an S-adenosylhomocysteine hydrolase inhibitor, a DOTH inhibitor, and zinc) [82] , and FR3109299A1 (a composition of artemether, azithromycin, and zinc) [83] .

Zinc possesses an appreciable antiviral activity, and its effects against SARS-CoV-2 are also well documented. The clinical data of zinc and its compositions show promise against COVID-19. The patent literature also supports the potential of zinc and its pharmaceutical compositions as possible treatments for COVID-19. The identification of the inventive composition of zinc indicates many foreseeable commercially available zinc-based medicines to combat COVID-19. However, the authors trust that many zinc-based compositions are still unexplored, and there is great scope to assess a large number of the zinc-based compositions for use against COVID-19.

Zinc, an essential nutrient for human health, has been used in clinical practice as a medicine, immune booster, and food supplement ( Figure 1 ) [10, 14] . SARS-CoV-2 (RNA virus) enters human cells via the ACE-2 receptors, and requires RdRp for its replication [6, 8] . RdRp is a major target for antiviral drug research. Studies have shown that increased intracellular concentration of zinc interferes with the proteolytic processing of polyproteins in several RNA viruses. Increased intracellular concentrations of zinc have also demonstrated inhibition of the isolated RdRp complex, purified recombinant RdRp, and the replication of coronavirus in tissue culture [41] . The zinc ions also suppress/lower the expression of the ACE-2 receptors, preventing the entry of SARS-CoV-2 into the cells [29] . Therefore, zinc demonstrates the dual character of prophylactic and therapeutic intervention for COVID-19.

Zinc and its compositions are in clinical trials to prevent and treat COVID-19 (Table 3 ). The data shown in Table 3 also reveal 3 studies in phase 1, 9 studies in phase 2, 12 studies in phase 3, and 4 studies in phase 4. Among these 28 studies, 18 studies are related to the treatment of COVID-19, 5 are related to the prevention of COVID-19, 4 are related to the use of zinc for supportive care, and 1 study relates to post-COVID-19 smell and taste dysfunction. Seven studies were conducted in the United States; one each in Iraq, Indonesia, Singapore, Thailand, Canada, Australia, and Pakistan; two in India; four each in Saudi Arabia and Egypt; three in Tunisia, and one study's location is undisclosed. Most of the clinical studies [26] have been planned as randomized clinical trials. It is also important to note that only one study (NCT04475588) has revealed its clinical outcomes. Two studies (NCT04590274 and NCT04528927) have been withdrawn. The literature also includes a clinical study (NCT04342728) related to the use of zinc gluconate, vitamin C, and their combination to shorten the treatment of COVID-19 [84] . However, the results of this study were not encouraging; therefore, it has been stopped for ineffectiveness. The compositions of zinc mentioned in Table 3 consist of one or more drugs/elements selected from hydroxychloroquine, azithromycin, vitamin C, vitamin D, N-acetylcysteine, elderberry, quercetin, ivermectin, doxycycline, insulin, gabapentin, itolizumab, heparin, acetaminophen, dexamethasone, chlorine dioxide, famotidine, lactoferrin, green tea extract, vitamin B12, methylene blue solution, phenformin, resveratrol, selenium, extract of Psidii guava, nitazoxanide, ribavirin, chloroquine, darunavir, ritonavir, and bromelain. The results of one clinical study (NCT04322513) have demonstrated the role of vitamin D against COVID-19 [85] . Accordingly, the important combination of zinc and vitamin D may provide synergistic effects to deal with COVID-19.

Our search revealed many patents/patent applications for pharmaceutical compositions of zinc for use against COVID-19 (Table 4) . Table 4 provides a summary of 29 patents/patent applications, of which 2 were published in 2020, 26 in 2021, and 1 in 2022. This pattern is expected, because the first COVID-19 case was identified in December 2019, and scientists started working on COVID-19 treatments in 2020. The majority of these patent applications have been filed in the United States (16), followed by India (4), Russia (3), Spain (2), Australia (1), the United Kingdom (1), China (1), and Colombia (1) (Figure 3) .

It is interesting to note that most of these compositions or their equivalent compositions are in clinical trials (Table 3 ). In almost all of the clinical studies and patent specifications, zinc has been used in the form of its salts (zinc acetate, zinc sulfate, zinc lactate, zinc aspartate, zinc undecylenate, zinc pyrithione, zinc gluconate, zinc oxide, zinc picolinate, zinc iodide, zinc chloride, zinc citrate, zinc carbonate, zinc hydroxide, zinc fluoride, zinc bromide, zinc sulfonate, zinc glucuronate, zinc bisglycinate, and zinc pyruvate). Remdesivir [6] , Paxlovid [7] , and molnupiravir [8] are approved treatments for COVID-19. However, no clinical study or patent literature has been found relating to the specific combination of zinc with remdesivir, Paxlovid, or molnupiravir. This can be considered as an opportunity for further research of treatments for COVID-19. However, the possibility of the interaction of zinc with antiviral drugs must be assessed before COVID-19 treatment, as zinc has been reported to interfere with the absorption of many antivirals (Figure 1) . A zinc ionophore helps in the transport of zinc at the target site, such as a cell. Many clinical studies and patent applications have used compositions of zinc with a zinc ionophore (e.g., alpha defensin 5, quercetin, curcumin and epigallocatechin gallate, silymarin, hesperidin, diosmin, neral, geranial, and citronellal). High doses of zinc or its regular intake may cause copper deficiency or side effects [52] . The targeted delivery of zinc utilizing a zinc ionophore may reduce these effects. Hypertensive people are considered to be at risk of COVID-19. ACE-2, a metalloenzyme, is implicated in the pathogenesis of hypertension. Zinc lowers the expression of ACE-2, and is also an immune booster; therefore, it is believed that zinc compositions may provide better therapeutic outcomes when used along with antihypertensive ACE inhibitors (e.g., captopril, lisinopril, ramipril, etc.) [12] . The use of zinc compositions for enriching the human immune system and to prevent the secondary complications of COVID-19 in high-risk populations (e.g., geriatric/immunocompromised patients, patients suffering from chronic diseases, medical and paramedical professionals, etc.) has also been claimed [56] .

Despite the many benefits associated with zinc, some studies have warned against the excessive use of zinc among COVID-19 patients [86, 87] . Zinc is needed for the growth of many pathological fungi, including Mucorales, which cause fatal mucormycosis [86, 88] . Some others have reported that zinc might have a negative impact, and high zinc levels in hepatitis can increase the viral load by blocking the production of interferons (IFN-λ) [89] , induce apoptosis in T cells, B cells, and thymocytes [90, 91] , and lead to copper deficiency, which can cause anemia and leukopenia [92] .

Zinc can provide positive or negative effects based on the condition of the consumer/patient. However, zinc supplements are not expensive, and are readily available on the market. This facilitates the overuse of zinc supplements among COVID-19 patients. Accordingly, zinc supplements must be used under medical supervision. Most of the literature supports the notion that zinc can provide beneficial effects among mild-to-moderate COVID-19 patients, wherein the dose, duration of zinc treatment, and condition of the patient are important aspects during COVID-19 therapy. Accordingly, many inventions of zinc-based compositions have been developed for use against COVID-19. The identification of the inventive composition and current clinical trials of zinc-based compositions indicates many foreseeable commercially available zinc compositions to combat COVID-19. However, there is a need to assess the efficacy of zinc supplements and inventive compositions among severe COVID-19 cases requiring intensive care [87] . 

Wuhan to world: The COVID-19 pandemic

COVID-19: From the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment

A systematic review and meta-analysis of risk factors associated with severity and death in COVID-19 patients. Can

WHO Coronavirus (COVID-19) Dashboard. Available online

Assessment of quality of life among health professionals during COVID-19: Review

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19

Discovery, development, and patent trends on molnupiravir: A prospective oral treatment for COVID-19

Innovations and development of COVID-19 vaccines: A patent review

Recent aspects of the effects of zinc on human health

Zinc as a Drug for Wilson's disease, non-alcoholic liver disease and COVID-19-related liver injury

Possible benefits of zinc supplement in CVD and COVID-19 comorbidity

Medicinal plants and zinc: Impact on COVID-19 pandemic

Potential molecular mechanisms of zinc-and copper-mediated antiviral activity on COVID-19

Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities

COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?

The Implications of zinc therapy in combating the COVID-19 global pandemic

Potential health benefits of zinc supplementation for the management of COVID-19 pandemic

Trace element inc, a nature's gift to fight unprecedented global pandemic COVID-19

Zinc and COVID-19: Basis of current clinical trials

Genetic polymorphisms and zinc status: Implications for supplementation in metabolic diseases

Zinc intakes and health outcomes: An umbrella review

Evaluation of zinc, copper, and Cu:Zn ratio in serum, and their implications in the course of COVID-19

Zinc and its importance for human health: An integrative review

Potential adjuvant treatment for COVID-19 patients

Determination of zinc and copper absorption at three dietary Zn-Cu ratios by using stable isotope methods in young adult and elderly subjects

International zinc nutrition consultative group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Role of NRF2 and sirtuin activators in COVID-19

Cytokine storm induced by SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in

Zinc-suppressed inflammatory cytokines by induction of A20-mediated inhibition of nuclear factor-κB

SciFinder Scholar 2006: An empirical analysis of research topic query processing

The United States Patent and Trademark Office. Patent Full-Patent Database

Discovery, development, inventions, and patent trends on mobocertinib succinate: The first-in-class oral treatment for NSCLC with EGFR exon 20 insertions

Innovations and patent trends in the development of USFDA approved protein kinase inhibitors in the last two decades

Synthetic molecules as DprE1 inhibitors: A patent review

Zinc for Treating COVID-19. WO2021216562A1

Methods of Treating COVID-19 Infection. US11166971B2

Aldehyde Functional Monoterpenoids for the Treatment of Coronavirus Infection

Method and Composition for Treating Upper Respiratory Tract Inflammatory and Infectious Diseases

Combination Therapy for Coronavirus Infections Including the Novel Corona Virus (COVID-19). US10987329B1

Therapy for Viral Infections Including the Novel Corona Virus (COVID-19). US11026909B1, 8

Pharmaceutical Composition and Its Use to Inhibit Membrane ACE2 Expression. US11135196B1

Antiviral Composition. RU2740657C1

Antiviral Composition. RU2740660C1

Technology of Rehabilitation-Preventive Nutritional Support in Coronavirus Infection. RU2735723C1

Zinc Porters, and Their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers. US2021402001A1

Zinc and Copper for the Prophylaxis and Treatment of COVID-19

Therapeutic Compositions, Products of Manufacture and Methods for Ameliorating or Preventing Coronavirus Infection

Compositions and Methods for Dietary Enhancement of Immune System Function. US2021386779A1

Use and Method for Broad-Spectrum Prophylaxis and Treatment of Viral Infections Caused by SARS-CoV-2 and Other Emerging Viruses. US20210393679A1

Quadruple Regime Using Azithromycin 500 mg Daily Plus Vitamin C Gram Twice Daily Plus Zinc 500 mg Daily Plus Low-Dose Aspirin 100 mg Daily for 12 Weeks to be used as Prophylaxis to Prevent COVID-19 Virus/Corona Virus/SARS COVID 2 Virus Infection in Nursing Home/Aged Care Population in Illawarra Region NSW Australia

Food Supplements for the Prevention of COVID-19. WO2021191864A1

Method for Treatment of Coronavirus Infection

Improved Immunomodulator Compositions and Viral Pathogen Treatments. WO2021245365A1

Binary Complex of an Organic Zinc Chelate and Flavonoids and Composition Comprising It for Stimulating the Immune System and Enhancing Resistance to Viral or Bacterial Infectious Diseases

A Synergistic Formulation for Management of Respiratory Pathogens Including Coronaviruses. WO2021224836A1

Compositions and Methods for Treating Virus Infection

Composition and Method for the Treatment of COVID-19. US2021346426A1

Product for Preventing and Treating New Coronavirus and Preparation Method Thereof

Plant Health-Care Beverage for Improving Human Immunity. CN113208020A

Pharmaceutical Composition and Kit-of-Parts for Use against Infections Caused by Coronaviruses. WO2021224659A1

New Composition for use to Treat and Prevent Infections by COVID-19 and Other Coronaviruses

Ophthalmic Compositions for Treating Coronaviruses. WO2021198908A1

Method of Treating Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). US2022016053A1

Therapeutic Combinations of Drugs for Treating, Preventing, Ameliorating or Preventing Coronavirus Infection

Camellia Nitidissima Caffeine and Chlorogenic Acid Composition for Resisting Novel Coronavirus as well as Preparation Method and Application of Camellia Nitidissima Caffeine and Chlorogenic Acid Composition. CN111450100A

Food Product with Immunomodulator Effect. WO2021074706A1

Methods for Treating Coronavirus Infection and Resulting Inflammation-Induced Lung Injury. WO2021183456A1

Tgf-Beta Inhibition, Agents and Composition Therefor. WO2021186396A2

Iodine Compounds for Treating Respiratory Pathogens. WO2021195017A1

Compositions and Methods for Treatment of COVID-19. US20210346453A1

Methods and Compounds for Preventing and Arresting COVID-19 Morbidity and Mortality, Via Inhibition of Interleukin-6, Tnf-Alpha, and Other Cytokines, and via Reduction of C-Reactive Proteins

Oral Sanitizer and Immune Support for Viral and Bacterial Prevention. US20210330587A1

Pharmaceutical Compositions for Treating Corona Virus Disease. WO2021205437A1

Combination of Artemether and Azithromycin in the Treatment of Epidemics such as Coronavirus

Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: The COVID A to Z randomized clinical trial

Vitamin D Serum Levels in Subjects Tested for SARS-CoV-2: What Are the Differences among Acute, Healed, and Negative COVID-19 Patients? A Multicenter Real-Practice Study

Mucormycosis in COVID-19: Is zinc a silent killer in India? Indian

To zinc or not to zinc for COVID-19 prophylaxis or treatment?

Mucormycosis medications: A patent review

Zinc is a potent and specific inhibitor of IFN-λ3 signalling

Zinc is a novel intracellular second messenger

Preferential induction of apoptosis in mouse CD4+CD8+ alpha beta TCRloCD3 epsilon lo thymocytes by zinc

Zinc toxicity

The authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia, for funding this work through the project number IF-2020-NBU-212.

The authors declare no conflict of interest.